{
    "schema_version": "2.0",
    "schema_rules": [
        "Extract complete phrases with full clinical context",
        "Preserve original clinical language and abbreviations, do not standardise",
        "Include any relevant qualifiers and context, including measures of severity",
        "Extract dates as year/month only where available and clearly attached to concept",
        "Exclude fields where information missing - do not infer or make up new information"
    ],
    "schema_structure": {
        "primary_cancer": {
            "description": "Main primary cancer and related facts that are the main subject of letter. Populate fields only where information present.",
            "fields": {
                "site": "Primary main organ site or topography (e.g. - ovary, breast, brain, lung, etc) and more detailed localisation (e.g. right, upper lobe, cerebellum)",
                "year": "Year of initial diagnosis (YYYY) if given",
                "month": "Month of initial diagnosis (1-12) if given",
                "metastases": "Location of any confirmed metastases, including nodal disease",
                "tnm_stage": "Current TNM staging for main cancer. Do NOT infer.",
                "other_stage": "Other cancer staging, e.g. stage 1,2,3,4. Do NOT infer.",
                "histopathology_status": "Histopathological classification, morphology, and findings for historical cancer",
                "biomarker_status": "Status of any identifying biomarkers for main cancer, including genomic biomarkers"
            },
            "cancer_timeline": {
                "description": [
                    "Timeline of events for main primary cancer leading to the present consultation. For the types given below, the same letter text can be filled as multiple types if there is overlap (e.g. cisplatin stopped due to toxicity, commenced on hormone therapy",
                    "treatment_systemic_start captures whereever a new systemic therapy regimen, e.g. chemo or immuno, was commenced",
                    "treatment_systemic_change captures pausing, dose reduction, stopping, of systemic therapy, and must include reasoning if given e.g. toxicity or ineffectiveness",
                    "treatment_radiotherapy and treatment_surgery capture these types of treatment, and should include complications if given",
                    "anatomical_finding captures spread to anatomical locations, i.e. metastases, and should include modality of investigation if given",
                    "laboratory_finding captures lab or pathology results, for example biomarkers",
                    "other_progress_or_event captures general events, e.g. patient reported measures, emergency admissions; or those representing positive or negative cancer progress, e.g. in remission",
                    "clinical_trial_update captures trial related events"
                ],
                "cardinality": "multiple",
                "allowed_types": [
                    "treatment_systemic_start",
                    "treatment_systemic_change",
                    "treatment_radiotherapy",
                    "treatment_surgery",
                    "anatomical_finding",
                    "laboratory_finding",
                    "other_progress_or_event",
                    "clinical_trial_update"
                ],
                "fields": {
                    "type": "Event type from allowed_types",
                    "value": "Extracted event text",
                    "year": "Year of event (YYYY) if given",
                    "month": "Month of event (1-12) if given"
                }
            }
        },
        "other_cancers": {
            "description": "Array of historical cancer diagnoses and facts, if any. Populate fields only where information present.",
            "repeatable": true,
            "fields": {
                "site": "Organ site or topography, and more detailed localisation",
                "year": "Year of historical cancer diagnosis (YYYY) if given",
                "month": "Month of historical diagnosis (1-12) if given",
                "metastases": "Location of confirmed metastases, including nodal disease. Positive mentions only.",
                "tnm_stage": "TNM staging for historical cancer",
                "other_stage": "Other cancer staging",
                "histopathology_status": "Histopathological classification, morphology, and findings for historical cancer",
                "biomarker_status": "Status of any identifying biomarkers for historical cancer, including genomic biomarkers",
                "latest_situation": "Last given treatment status for historical cancer, for example in remission, or under active surveillance"
            }
        },
        "patient_facts": {
            "description": "Current, active patient information given in the letter, often as part of history-taking or examination or latest investigation.",
            "cardinality": "multiple",
            "allowed_types": [
                "comorbidity",
                "current_symptom",
                "examination_finding",
                "performance_status",
                "quality_of_life_finding",
                "investigation_finding"
            ],
            "fields": {
                "type": "Type of patient fact from allowed_types",
                "value": "Extracted fact information"
            }
        },
        "status_updates": {
            "description": [
                "clinical_summary gives a one line summary of cancer progression background, and a one line clinical expert impression to sumamrise the active consultation. Be factual and concise, do not make inferences.",                
                "This summarises different types of updated status for the cancer, treatment, patient, and plan",
                "latest_treatment_response is the latest response to a round of treatment (for example - no tumour size response)",
                "latest_treatment_toxicity captures new toxicity events (for example - experiencing grade 3 toxicity)",
                "update_to_treatment captures any changes to treatment, including dose reduction, or stopping, or starting new therapy",
                "updated_patient_functional_status captures changes such as frailty or performance",
                "planned_investigation and follow_up_referral capture the next investigation and follow-up or referral steps outlined in the letter",
                "death_flag should be true if the letter indicates that the patient has passed away"
            ],
            "cardinality": "multiple",
            "allowed_types": [
                "clinical_summary",
                "latest_treatment_response",
                "latest_treatment_toxicity",
                "update_to_treatment",
                "updated_patient_functional_status",
                "planned_investigation",
                "follow_up_referral",
                "death_flag"
            ],
            "fields": {
                "type": "Type of new status from allowed_types",
                "value": "Extracted status information"
            }
        }
    },
    "schema_example": {
        "primary_cancer": {
            "site": "lung, right upper lobe",
            "year": 2024,
            "month": 1,
            "metastases": "widespread bone metastases, bilateral adrenal metastases",
            "tnm_stage": "T4N2M1c",
            "other_stage": "Stage IV",
            "histopathology_status": "adenocarcinoma",
            "biomarker_status": "EGFR mutation positive, PDL1 80%, ALK negative",
            "cancer_timeline": [
                {
                    "type": "anatomical_finding",
                    "value": "CT chest shows 6.8cm right upper lobe mass with mediastinal and hilar lymphadenopathy",
                    "year": 2024,
                    "month": 3
                },
                {
                    "type": "anatomical_finding",
                    "value": "PET-CT confirms FDG-avid right upper lobe primary with widespread skeletal metastases",
                    "year": 2024,
                    "month": 3
                },
                {
                    "type": "laboratory_finding",
                    "value": "EGFR mutation detected in circulating tumor DNA",
                    "year": 2024,
                    "month": 3
                },
                {
                    "type": "treatment_systemic_start",
                    "value": "Started on Osimertinib 80mg daily",
                    "year": 2024,
                    "month": 3
                },
                {
                    "type": "treatment_radiotherapy",
                    "value": "Completed palliative radiotherapy 20Gy in 5 fractions to symptomatic T4 vertebral metastasis",
                    "year": 2024,
                    "month": 4
                },
                {
                    "type": "treatment_systemic_change",
                    "value": "Osimertinib dose reduced to 40mg daily due to grade 3 rash",
                    "year": 2024,
                    "month": 4
                }
            ]
        },
        "other_cancers": [
            {
                "site": "breast, left",
                "year": 2015,
                "month": 6,
                "tnm_stage": "pT1cN0M0",
                "other_stage": "Stage I",
                "histopathology_status": "Grade 2 invasive ductal carcinoma",
                "biomarker_status": "ER positive (8/8), PR positive (6/8), HER2 negative",
                "latest_situation": "Disease free, completed 5 years of tamoxifen in 2020"
            },
            {
                "site": "skin, right shoulder",
                "year": 2019,
                "month": 8,
                "tnm_stage": "pT2aN0M0",
                "other_stage": "Stage IB",
                "histopathology_status": "Melanoma, Breslow thickness 2.1mm, no ulceration",
                "biomarker_status": "BRAF V600E mutation not detected",
                "latest_situation": "Under annual surveillance with dermatology, no evidence of recurrence"
            }
        ],
        "patient_facts": [
            {
                "type": "performance_status",
                "value": "ECOG PS 2 due to bone pain and fatigue"
            },
            {
                "type": "comorbidity",
                "value": "Type 1 diabetes with peripheral neuropathy"
            },
            {
                "type": "comorbidity",
                "value": "Chronic anxiety on regular medication"
            },
            {
                "type": "current_symptom",
                "value": "Right-sided chest pain requiring regular paracetamol and codeine"
            },
            {
                "type": "current_symptom",
                "value": "Breathlessness on minimal exertion"
            },
            {
                "type": "examination_finding",
                "value": "Reduced air entry right upper zone with percussion dullness"
            },
            {
                "type": "quality_of_life_finding",
                "value": "Requires walking frame due to bone pain affecting spine and left hip"
            },
            {
                "type": "investigation_finding",
                "value": "CT 15/03/24 shows partial response in primary mass, stable bone metastases"
            }
        ],
        "status_updates": [
            {
                "type": "clinical_summary",
                "value": "Late stage breast cancer with widespread metastases. Partial response to Osimertinib with improving symptoms but treatment complicated by grade 3 rash requiring dose reduction"
            },
            {
                "type": "latest_treatment_response",
                "value": "30% reduction in size of primary tumor and reduction in bone pain following radiotherapy"
            },
            {
                "type": "latest_treatment_toxicity",
                "value": "Grade 3 papulopustular rash affecting >30% body surface area, requiring dose reduction and oral antibiotics"
            },
            {
                "type": "update_to_treatment",
                "value": "Continuing Osimertinib 40mg daily with improved tolerability following dose reduction"
            },
            {
                "type": "updated_patient_functional_status",
                "value": "Deterioration in mobility requiring increased care package and walking aids"
            },
            {
                "type": "planned_investigation",
                "value": "CT chest/abdomen/pelvis in 6 weeks to assess response"
            },
            {
                "type": "follow_up_referral",
                "value": "Review in lung oncology clinic in 2 weeks with blood results"
            }
        ]
    }
}